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IMPORTANCE Carotid endarterectomy (CEA) among asymptomatic patients involves a
trade-off between a higher short-term perioperative risk in exchange for a lower long-term
risk of stroke. The clinical benefit observed in randomized clinical trials (RCTs) may not extend
to real-world practice.
OBJECTIVE To examine whether early intervention (CEA) was superior to initial medical
therapy in real-world practice in preventing fatal and nonfatal strokes among patients with
asymptomatic carotid stenosis.
DESIGN, SETTING, AND PARTICIPANTS This comparative effectiveness studywas conducted
from August 28, 2018, to March 2, 2020, using the Corporate DataWarehouse, Suicide Data
Repository, and other databases of the US Department of Veterans Affairs. Data analyzed
were those of veterans of the US Armed Forces aged 65 years or older who received carotid
imaging between January 1, 2005, and December 31, 2009. Patients without a carotid
imaging report, those with carotid stenosis of less than 50% or hemodynamically
insignificant stenosis, and those with a history of stroke or transient ischemic attack in the 6
months before index imaging were excluded. A cohort of patients who received initial
medical therapy and a cohort of similar patients who received CEAwere constructed and
followed up for 5 years. The target trial method was used to compute weighted Kaplan-Meier
curves and estimate the risk of fatal and nonfatal strokes in each cohort in the pragmatic
sample across 5 years of follow-up. This analysis was repeated after restricting the sample to
patients whomet RCT inclusion criteria. Cumulative incidence functions for fatal and nonfatal
strokes were estimated, accounting for nonstroke deaths as competing risks in both the
pragmatic and RCT-like samples.
EXPOSURES Receipt of CEA vs initial medical therapy.
MAIN OUTCOMES ANDMEASURES Fatal and nonfatal strokes.
RESULTS Of the total 5221 patients, 2712 (51.9%; mean [SD] age, 73.6 [6.0] years; 2678men
[98.8%]) received CEA and 2509 (48.1%; mean [SD] age, 73.6 [6.0] years; 2479men
[98.8%]) received initial medical therapy within 1 year after the index carotid imaging. The
observed rate of stroke or death (perioperative complications) within 30 days in the CEA
cohort was 2.5% (95% CI, 2.0%-3.1%). The 5-year risk of fatal and nonfatal strokes was lower
among patients randomized to CEA compared with patients randomized to initial medical
therapy (5.6% vs 7.8%; risk difference, −2.3%; 95% CI, −4.0% to −0.3%). In an analysis that
incorporated the competing risk of death, the risk difference between the 2 cohorts was
lower and not statistically significant (risk difference, −0.8%; 95% CI, −2.1% to 0.5%). Among
patients whomet RCT inclusion criteria, the 5-year risk of fatal and nonfatal strokes was 5.5%
(95% CI, 4.5%-6.5%) among patients randomized to CEA and was 7.6% (95% CI, 5.7%-9.5%)
among those randomized to initial medical therapy (risk difference, −2.1%; 95% CI, −4.4% to
−0.2%). Accounting for competing risks resulted in a risk difference of −0.9% (95% CI, −2.9%
to 0.7%) that was not statistically significant.
CONCLUSIONS AND RELEVANCE This study found that the absolute reduction in the risk of fatal
and nonfatal strokes associated with early CEAwas less than half the risk difference in trials
from 20 years ago and was no longer statistically significant when the competing risk of
nonstroke deaths was accounted for in the analysis. Given the nonnegligible perioperative
30-day risks and the improvements in stroke prevention, medical therapymay be an
acceptable therapeutic strategy.
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R andomized clinical trials (RCTs) have established thatcarotid endarterectomy (CEA) is beneficial in prevent-ing stroke in both asymptomatic1-3 and symptomatic
patients4,5with carotid stenosis. However, themost recent of
the 3 trials that established the clinical benefit of CEA com-
paredwithmedical therapy in asymptomatic patientswas ini-
tiated 25 years ago.1-3 In the intervening period, newpharma-
cological advances, such as high-potency statins6-9 and
improvedantiplatelet regimens,10,11 aswell asquality improve-
ments inthetreatmentofbloodpressure12,13anddiabetes14may
beassociatedwith the reducedstroke rateamongpatientswith
asymptomatic carotid stenosis. Empirical evidence in sup-
port of a reduction in stroke risk among patientswith asymp-
tomatic carotid stenosis has beenprovidedbya systematic re-
view of several studies.15 If the decrease in stroke rate among
patients with carotid artery stenosis is associated with im-
provements in primary stroke prevention, revascularization
may no longer be the preferred treatment strategy.
Since the first RCT was published that demonstrated the
superiority of CEA compared with medical therapy for
patients with asymptomatic carotid stenosis, concerns have
emerged that the outcomes seen in a clinical trial setting
may not be reproducible in non-RCT settings because of
demonstrated less optimal surgical outcomes,16-19 higher
complication rates in low-volume hospitals,20-22 and poor
patient selection.23,24 The risk to benefit ratio of interven-
tions may be less favorable outside of RCTs. In addition,
although a much larger clinical benefit has been observed in
treating patients with symptomatic carotid stenosis, most
interventions have been performed on patients with asymp-
tomatic carotid stenosis.25-28 Furthermore, substantial
international variation exists in using revascularization for
the treatment of asymptomatic carotid stenosis, suggesting
changing attitudes about the use of CEA. These changing
practice patterns indicate a need to improve understanding
of the long-term clinical benefit of this procedure outside of
an RCT.
In this study, we used data from the US Department of
Veterans Affairs (VA) and Medicare to mimic the design and
analysis methods of an RCT and to examine whether early
intervention (CEA) was superior to initial medical therapy in
real-world practice. We hypothesized that the clinical supe-
riority once observed in patients who received CEA has
diminished, making medical therapy a more favorable treat-
ment strategy in comparison. We also hypothesized that
among carefully selected patients, CEA may still be superior
to medical therapy.
Methods
The institutional review board of the University of California
SanFranciscoapproved this studyandwaived theneed forpa-
tientconsentbecause theresearch involvednomore thanmini-
mal risk to participants. This study was conducted from Au-
gust 28, 2018, toMarch2, 2020.We followed the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) reporting guideline.
Study Population, Data Sources, and Preliminary Screening
Using VA national data, we identified 219979 veterans of the
US Armed Forces aged 65 years or older with at least 1 visit to
a VA facility for primary care (eg, general medicine, women
clinic) or subspecialty care (eg, geriatrics, cardiology, endo-
crine, pulmonary, or neurology) who received diagnostic ca-
rotid imaging (ie, carotid ultrasonography, computed tomog-
raphy angiography, or magnetic resonance angiography)
between January 1, 2005, and December 31, 2009, as indi-
cated by Current Procedural Terminology (CPT) and Interna-
tional Classification of Diseases, Ninth Revision (ICD-9) codes
(eTable 1 in theSupplement).Tocreateacohortofpatientswith
asymptomatic carotid stenosis, we excluded all patientswith
carotid imaging test resultswhohadany formof strokeor tran-
sient ischemic attack (TIA) in the6monthsbefore the imaging
testusingahighly sensitive algorithmbasedon ICD-9 codes29;
wemodified the algorithm for this study to also exclude reti-
nal strokes and TIAs (eTable 2 in the Supplement).
All patient demographic information, administrativedata
(eg, comorbid conditions, utilization), vital signs, laboratory
data, and pharmacy data were retrieved from the VA Corpo-
rate DataWarehouse andMedicare data.30 Text clinical notes
for carotid image reports were identified from the VA Corpo-
rate Data Warehouse. Data on carotid revascularization were
retrieved from the VA Corporate Data Warehouse using the
ICD-9code forCEA(38.12), ICD-9codes for carotidartery stent-
ing (CAS) (00.61and00.63),CPTcode forCEA(35301), andCPT
codes forCAS (37215and37216).Deathandcauseofdeathwere
obtained fromtheSuicideDataRepository,which is jointly ad-
ministered by the US Department of Defense and the VA. The
Suicide Data Repository, created to track deaths by suicide
amongmilitarypersonnel, contains comprehensive cause-of-
death data for all US veterans.31
Using a previously developed natural language process-
ing algorithm,32weexcludedall carotid imaging results show-
ing stenosis of less than 50% or hemodynamically insignifi-
cantstenosis (Figure1).We importedall text reports forpatients
with at least 1 carotid imaging showing stenosis of 50% or
greater (n = 71839) intoadatabase forhumanscreening. In this
Key Points
Question Among patients with asymptomatic carotid stenosis, is
carotid endarterectomy superior to initial medical therapy in
preventing fatal and nonfatal stroke within 5 years of follow-up in
real-world practice?
Findings In this comparative effectiveness study of 5221 patients
with asymptomatic carotid stenosis, the absolute reduction in the
risk of fatal and nonfatal strokes associated with early carotid
endarterectomy treatment was less than half the reduction
observed in trials initiatedmore than 2 decades ago. The decrease
was not statistically significant when the competing risk of
nonstroke deaths was accounted for in the analysis.
Meaning Results of this study suggest that, given the up-front
perioperative risks associated with carotid endarterectomy and
the reduced benefit derived from revascularization, initial medical
therapymay be an acceptable treatment strategy for the
management of asymptomatic carotid stenosis.
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preliminary screening process, we identified all patientswho
had carotid imaging text reports indicating greater than 70%
carotid stenosis or a qualitative description of near occlu-
sion, critical stenosis, or severe stenosis. Subsequent medi-
cal record reviewwas used to confirm stenosis.We identified
13 371 potentially eligible patients with stenosis of 70% or
greater (Figure 1).
PatientMatching
Administrative data on baseline characteristics demon-
strated that patients who received CEA were different from
those who received initial medical therapy. For example, pa-
tients in the CEA cohort compared with patients in the initial
medical therapycohortwereyounger andexperienced less co-
morbidity (eg, coronaryarterydisease, chronicobstructivepul-
monary disease, and chronic kidney disease) (eTable 3 in the
Supplement).
The first step in our analytical strategywas to construct a
sample of patients in the initial medical therapy cohort who
were similar to those in the CEA cohort. We used propensity
score matching to identify these similar patients. Specifi-
cally, we fit a generalized boosted model for treatment (CEA
vs initialmedical therapy) as a function of covariates.33 Using
the estimated propensity scores, we used a nearest neighbor
match (with a caliper that varied between 0.2 and 0.8) to se-
lect patients fromthe initialmedical therapy cohortwhowere
similar to patients in the CEA cohort on the basis ofmeasured
covariates. At this stage, we retained all patientsmatched ac-
cording tomeasuredcovariatesbecauseweexpected somepa-
tients might be excluded during the medical record review
phase.
This first step in the analytical strategy created a cohort
of potentially eligible patients who were similar in measured
baseline covariates. To examine the degree to which this pa-
Figure 1. Carotid Cohort Construction
1911 Excluded
872 With <70% carotid stenosis
77 Designated as a nonsurgical candidate
823 Had stroke or TIA in previous 6 mo
139 Received procedure outside hospital
and lacked data
219 979 Male veterans aged ≥65 y with a potential
carotid image identified
13 371 With ≥70 carotid stenosis included
3795 Randomized to early intervention 
3795 Randomized to early intervention 
9576  Randomized to initial medical therapy 
3888 Randomized to initial medical therapy
170 446 With a carotid image report included
71 839 With ≥50% stenosis included
49 533 Excluded for having no carotid image report
58 468 Excluded for having <70% carotid stenosis
1520 Did not meet RCT inclusion criteria
13 371 Randomized
2712 Received CEA
Pragmatic sample
551 Received CAS
Pragmatic sample
2509 Received initial medical therapy
Pragmatic sample
2012 Received CEA
RCT-like sample
350 Received CAS
RCT-like sample
1890 Received initial medical therapy
RCT-like sample
Natural language processing 
Human review of carotid
image reports 
Propensity score matching
Medical record review
CAS indicates carotid artery stenting; CEA, carotid endarterectomy; RCT, randomized clinical trial; and TIA, transient ischemic attack.
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tientmatchingwas successful,we examined the risk of pneu-
monia (a traceroutcome)betweenthe2matchedsamples (CEA
vs initial medical therapy) within 1 year of the index carotid
imaging.Wefoundnodifference in the riskofpneumonia, sug-
gesting that matching was successful.
Medical Record Review
Next, we reviewed themedical record of each potentially eli-
gible patient to confirmboth carotid stenosis level and symp-
tom status (hemorrhagic or ischemic stroke or TIA in the 6
months before index imaging). We excluded patients with a
history of stroke or TIA in the6months before index imaging.
Patients with carotid stenosis levels between 50% and 70%
were also excluded because recent trials have included pa-
tients with a higher threshold of stenosis, and practice pat-
terns have moved toward revascularization of patients with
greater stenosis who are perceived at higher risk of stroke.34
We also collected from themedical record data on disease se-
verity (eg, ejection fraction,pulmonary function) thatwerenot
available innationalVAdata; dataon receipt of aspirin at base-
linebecauseaspirin isanover-the-countermedicationthatmay
not be dispensed by VA pharmacies; and data onwhether the
patient underwent a CEA or CAS andwhether the patient had
a history of remote stroke or TIA more than 6 months before
index carotid imaging. Details on the abstraction and quality
assurance protocols during themedical abstraction phase are
provided in eTable 4 in the Supplement.
Among the3795patientsdesignatedas theCEAcohort and
the 3888 propensity-matched patients in the initial medical
therapy cohort, 823 patients were excluded because of a pre-
vious stroke or TIA and 872 patients were excluded because
theydidnotmeet stenosis criteria. Also excludedwere 139pa-
tients with an ambiguous group classification because the
medical record review suggested they had received a proce-
dure from an outside hospital; however, we were unable to
verify the procedure in the VA or Medicare databases. More-
over,we excluded77patients from the initialmedical therapy
cohortwhen a clinician specifically documented in themedi-
cal record that the patient was not a surgical candidate.
After application of the exclusion criteria, the total co-
hort comprised 2712 patients who received CEA, 551 who re-
ceived CAS, and 2509 who received initial medical therapy
(Figure 1). Because too few patients who received CAS were
included, this study focused on the comparative effective-
ness of CEA vs initial medical therapy, and patients who un-
derwent CAS were excluded from all subsequent analyses.
Emulation of Previous Trials
We emulated the analyses used in the Asymptomatic Carotid
Surgery Trial (ACST),3 the last published RCT to estimate the
comparative effectiveness of CEAvs initialmedical therapy in
preventing fatal and nonfatal strokes. The analytical plan for
thepresent trial emulationwas tomimicnotonly theACSTbut
also clinical practice in that a clinician might choose initial
medical therapy for a patient but may later adopt a more ag-
gressive course, such as CEA, if the patient’s condition or ca-
rotid stenosis worsens. Because of delays in receiving treat-
ment after carotid imaging and the possibility that patients in
the initial medical therapy cohort may develop an indication
(ie, stroke or TIA) to switch toCEAorCAS,3we, as in theACST,
operationally defined the intervention cohort as follows: re-
ceipt of intervention (CEA) within the first year after carotid
imaging.Wealsodefined the initialmedical therapy cohort as
follows, similar to that in the ACST: absence of intervention
in theyearafter indexcarotid imaging (initialmedical therapy).
Thus, the target trial was of early intervention (within 1 year)
vs initial medical therapy (≥1 year after).
We constructed 2 alternative samples to emulate 2
variations in trials. First, we emulated an RCT with few
inclusion criteria (ie, a pragmatic RCT reflecting real-world
practice). Second, we emulated a trial that mimicked the
strict inclusion and exclusion criteria of carotid intervention
trials.3,35-37 For the pragmatic RCT emulation, all eligible
asymptomatic patients were included in the analyses (prag-
matic sample), whereas for the strict criteria emulation, the
analytical sample was restricted to those who met carotid
trial inclusion and exclusion criteria (RCT-like sample)
(eTable 5 in the Supplement).3,34,36
OutcomeMeasure and Follow-up
We considered time zero (baseline) to be the time of the first
carotid imagedemonstratingstenosis.As in theACST, thecom-
bined end point of fatal and nonfatal strokes (all territorial
strokes) was chosen as the primary outcome. Stroke that oc-
curred during the follow-up period was assessed using the
Tirschwell high-specificity algorithm.38
All patients were followed up for as long as 5 years from
the date of the first carotid image exhibiting stenosis of 70%
or greater.Wewereunable to incorporate into the analysis the
perioperative complicationof death associatedwithCEA.Un-
like in a trial in which randomization to surgical intervention
occurs quite rapidly, in real-world practice the delay between
index carotid imaging and receipt of CEA (treatment random-
ization) may be longer. Therefore, wewere unable to create a
meaningful time frame for examining the comparable 30-day
risk of death in the initial medical therapy cohort.
Statistical Analysis
In eachof the 2 analytic samples (pragmatic andRCT-like),we
conducted 3 different statistical analyses: (1) estimation of
crude 5-year stroke risk, (2) emulation of the ACST using tar-
get trial methods, and (3) emulation of the ACST using target
trialmethods and accounting for the competing risk of death.
A total of 6 analyses were performed.
First, we computed Kaplan-Meier estimates of a 5-year
stroke risk from the date of index imaging to allow compari-
sons of fatal and nonfatal stroke risk in this sample to risk in
other populations. Second, we used an analytical approach,
the target trial method, that allows for the assessment of ob-
servational data in amanner that emulates the analysis of an
RCT in which the active intervention can be applied at vary-
ing times after baseline.39-41 To minimize the immortal time
bias that can arise in anRCTwhen the interventionmaybe re-
ceived some time after baseline, we randomized each patient
at baseline to one of the 2 treatment cohorts (CEA or initial
medical therapy), possibly contrary to the treatment that the
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patient actually received (see the Discussion for further de-
tail on the target trial method).
Because this study was not truly an RCT, patients whose
actual treatmentdidnotmatchtherandomizedtreatmentwere
censored on the date they received their actual treatment (ie,
the date on which the patient diverged from the randomized
treatment). Patientswere followedupafter baselineusing the
observational data until the first of 4 events occurred: (1) fa-
tal or nonfatal stroke (outcome), (2) end of the study period
(administrative censoring 5 years after baseline), (3) treat-
ment status became inconsistent with the randomized treat-
ment status (treatment switching), or (4) enrollment inMedi-
care Advantage (health maintenance organization) between
baseline and 1 year (censored because procedures and diag-
noses recordedunder thoseplanswerenot available).42 Thus,
patients who were randomized to the initial medical therapy
cohort and who subsequently underwent CEA within 1 year
wouldbecensoredbecauseof treatment switchingon thedate
theyunderwentCEA;once theyunderwentCEA(within1year),
their current treatment was no longer consistent with the co-
hort towhich theywere randomized (initialmedical therapy).
Similarly,patientswhowere randomizedto theCEAcohortand
whohad not undergone CEAwithin 1 yearwould be censored
after 1 year (because their treatmentat 1 yearwas, at thatpoint,
no longer consistent with the cohort to which they were ran-
domized). Patients who received concurrent CAS and CEA,
coronary artery bypass graft concurrent with CEA, or aortic
valve replacementconcurrentwithCEAwerealsocensoredbe-
cause their treatment was not consistent with the cohort to
which theywere randomized.Weconsideredaconcurrentpro-
cedure to be one that occurred within 1 day of the CEA.
Because the actual choice of treatment (CEA vs initial
medical therapy) may have depended on patients’ baseline
and postbaseline risk and prognostic factors, we accounted
for informative censoring due to treatment switching by
incorporating inverse probability of censoring weights
(IPCW) in the analysis. We estimated the IPCW using a Cox
proportional hazards regression model that included mea-
sured baseline (time invariant) and time-varying covariates
(the full list of variables included in the censoring model is
provided in eTable 6 in the Supplement). We then fit a Cox
proportional hazards regression model for the outcome (fa-
tal and nonfatal strokes) as a function of an indicator vari-
able for the randomized treatment cohort (CEA vs initial
medical therapy) and incorporated the time-varying IPCW.
Similar to what was observed in the ACST, regression diag-
nostics in this study revealed violations of the proportional
hazards regression assumption (including crossing CEA and
initial medical therapy survival curves); thus, we focused
on estimating and reporting 5-year fatal and nonfatal stroke
risk. Specifically, we estimated the 5-year risk of fatal and
nonfatal strokes in the CEA and initial medical therapy
cohorts incorporating the IPCW, and then we computed the
risk difference by comparing the CEA cohort with the initial
medical therapy cohort. We computed the end point and
95% CI estimate of the 5-year risk and risk difference from
the 50th, 2.5th, and 97.5th percentiles of the bootstrap dis-
tribution for the risks and risk difference.
Third, since thepublicationof theACST in2004,3 account-
ing for competing riskshasbecomestandard in survival analy-
ses. To reflect current statistical practice in survival analysis,
we accounted for competing risks (deaths due to causes other
than stroke) and repeated the target trial analyses described
earlier.43Todoso,weestimatedthecumulative incidence func-
tions for fatal andnonfatal strokes in theCEAand initialmedi-
cal therapy cohorts, accounting for nonstroke deaths as com-
peting risks. These cumulative incidence functions were
weighted by the time-varying IPCW.
Statistical significance at the α = .05 levelwas inferred on
the basis of the bootstrapped CI for the cumulative incidence
function curves. Analyses were performed using SAS Enter-
priseGuide, version 7.1 (SAS Institute Inc) andR, version 3.6.1
(R Foundation for Statistical Computing).
Results
Baseline Characteristics
Of the total 5221patients,2712 (51.9%;mean[SD]age,73.6 [6.0]
years;2678men[98.8%]) receivedCEAand2509(48.1%;mean
[SD] age, 73.6 [6.0] years; 2479men [98.8%]) received initial
medical therapywithin 1 year after the index carotid imaging.
Table 1 provides baseline characteristics of the propensity-
matched sample comparing patients in the CEA cohort with
those in the initial medical therapy cohort. The baseline so-
ciodemographic characteristics of the patients were similar,
with no difference in mean age, race/ethnicity, marital sta-
tus, andMedicaidenrollment.Standardizeddifferencesamong
58 baseline variables were less than 0.1 except in 2 variables
(remotestrokeandenrollment inMedicareManagedCare).The
prevalenceof remote strokewas less commonamong theCEA
cohortcomparedwiththe initialmedical therapycohort (22.0%
[n = 597] vs 27.1% [n = 681]; standardized difference, −0.11).
In addition, patients in the CEA cohort were less commonly
enrolled inMedicaremanaged care at baseline (283 [10.4%]vs
406 [16.2%]; standardized difference, −0.17) (Table 1).
Pragmatic Sample
Observed Risk of Stroke and Death per Actual Treatment Received
The observed risk of stroke or death (perioperative complica-
tions)within30days intheCEAcohortwas2.5%(95%CI,2.0%-
3.1%) in the pragmatic sample. The observed 5-year risk of fa-
tal or nonfatal stroke among patients with carotid stenosis in
thepragmatic samplewas7.5%(95%CI,6.5%-8.7%) in theCEA
cohort and 6.9% (95% CI, 5.8%-8.1%) in the initial medical
therapy cohort (Table 2). Five-year survival in the pragmatic
sample was 73.3% (95% CI, 71.6%-74.9%) for the CEA cohort
and 66.9% (95% CI, 65.0%-68.7%) for the initial medical
therapy cohort.
Target Trial Results
The baseline postrandomization characteristics for patients
randomized to the 2 strategies (as part of the target trial) are
provided in eTable 7 in the Supplement. After adjusting for
baseline characteristics and incorporating the IPCW, the5-year
risk of fatal and nonfatal strokes was lower among patients
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Table 1. Baseline Characteristics of Patients in Both Treatment Cohorts
Characteristic
No. (%)
Standardized
difference
CEA cohort
(n = 2712)
Initial medical
therapy cohort
(n = 2509)
Age, mean (SD), y 73.6 (6.0) 73.6 (6.0) −0.043
Race/ethnicity
White 2577 (95.0) 2368 (94.4) 0.029
Black 107 (4.0) 111 (4.4) −0.024
Other 28 (1.0) 30 (1.2) –0.016
Hispanic 94 (3.5) 93 (3.7) –0.013
Men 2678 (98.8) 2479 (98.8) –0.005
Married 1594 (58.8) 1460 (58.2)
Veteran priority score
High 2178 (80.3) 2013 (80.2) 0.002
Low 509 (18.8) 463 (18.5) 0.008
Unknown/missing 25 (0.9) 33 (1.3) –0.037
Enrolled in Medicaid 133 (4.9) 111 (4.4) 0.023
Enrolled in Medicare HMO 283 (10.4) 406 (16.2) –0.170
Comorbid conditions
Hypertension 2400 (88.5) 2224 (88.6) –0.005
Hyperlipidemia 2352 (86.7) 2187 (87.2) –0.013
Diabetes 1061 (39.1) 985 (39.3) –0.003
Ischemic heart disease 1264 (46.6) 1146 (45.7) 0.019
Remote stroke or TIA (>6 mo prior) 597 (22.0) 681 (27.1) –0.119
Hemiplegia or other paralytic syndrome 51 (1.9) 51 (2.0) –0.011
Peripheral vascular disease 655 (24.2) 630 (25.1) –0.022
Abdominal aortic aneurysm 146 (5.4) 143 (5.7) –0.014
Atrial fibrillation 258 (9.5) 190 (7.6) –0.070
Arrhythmia other than atrial fibrillation 148 (5.5) 128 (5.1) 0.016
Valvular heart disease 206 (7.6) 174 (6.9) 0.026
DVT or PE 25 (0.9) 19 (0.8) 0.018
Hepatitis 32 (1.2) 19 (0.8) 0.043
Rheumatoid arthritis 31 (1.1) 29 (1.2) –0.001
Pulmonary fibrosis 14 (0.5) 17 (0.7) –0.021
Prostate cancer 158 (5.8) 111 (4.4) 0.064
Congestive heart failure
Severe (EF <35%) 110 (4.1) 118 (4.7) –0.032
Mild (EF ≥35%) 1218 (44.9) 1123 (44.8) 0.003
Missing EF 37 (1.4) 29 (1.2) 0.006
No congestive heart failure 1347 (49.7) 1239 (49.4) 0.006
Chronic obstructive pulmonary disease
Moderate/severe 211 (7.8) 219 (8.7) –0.035
Mild 227 (8.4) 192 (7.7) 0.026
Unknown severity 229 (8.4) 208 (8.3) 0.006
No chronic obstructive
pulmonary disease
2045 (75.4) 1890 (75.3) 0.002
Chronic kidney disease
Severe (GFR <30) 160 (5.9) 149 (5.9) –0.002
Mild (GFR ≥30) 1104 (40.7) 1026 (40.9) –0.004
No chronic kidney disease 1448 (53.4) 1334 (53.2) 0.005
(continued)
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Table 1. Baseline Characteristics of Patients in Both Treatment Cohorts (continued)
Characteristic
No. (%)
Standardized
difference
CEA cohort
(n = 2712)
Initial medical
therapy cohort
(n = 2509)
Vital signs
Systolic BP
Normal (<120) 427 (15.7) 391 (15.6) 0.004
Prehypertension (120-139) 1271 (46.9) 1142 (45.5) 0.027
High BP stage 1 (140-159) 663 (24.5) 657 (26.2) –0.04
High BP stage 2 (≥160) 338 (12.5) 303 (12.1) 0.012
Unknown 13 (0.5) 16 (0.6) –0.021
Diastolic BP
Normal (<80) 2130 (78.5) 1983 (79.0) –0.012
Prehypertension (80-89) 437 (16.1) 414 (16.5) –0.011
High BP stage 1 (90-99) 113 (4.2) 83 (3.3) 0.045
High BP stage 2 (≥100) 19 (0.7) 13 (0.5) 0.023
Unknown 13 (0.5) 16 (0.6) –0.212
Body mass index
Underweight 24 (0.9) 24 (1.0) –0.008
Normal or healthy weight 645 (23.8) 639 (25.5) –0.039
Overweight 1203 (44.4) 1094 (43.6) 0.015
Obese 810 (29.9) 715 (28.5) 0.031
Unknown 30 (1.1) 37 (1.5) –0.033
Procedure
Defibrillator 18 (0.7) 27 (1.1) –0.044
Pacemaker 40 (1.5) 36 (1.4) 0.003
Mental health in past year
Posttraumatic stress disorder 73 (2.7) 60 (2.4) 0.019
Depression 26 (1.0) 14 (0.6) 0.046
Anxiety 78 (2.9) 58 (2.3) 0.036
Psychosis 84 (3.1) 72 (2.9) 0.013
Social and behavioral risk factors
Current smoker 855 (31.5) 827 (33.0) –0.031
Alcohol abuse in past year 204 (7.5) 178 (7.1) 0.016
Drug abuse in past year 32 (1.2) 31 (1.2) –0.005
Utilization
≥1 Intensive care unit visit 0.071
≥1 Hospital admission 520 (19.2) 426 (17.0) 0.057
Functional status
Nursing home in past year 17 (0.6) 21 (0.8) –0.025
Medication
Antiplatelet 2322 (85.6) 2129 (84.9) 0.022
Antiarrhythmic 39 (1.4) 32 (1.3) 0.014
Corticosteroid 233 (8.6) 204 (8.1) 0.017
Benzodiazepine 232 (8.6) 250 (10.0) –0.049
Opioid 181 (6.7) 152 (6.1) 0.025
Antianginal 519 (19.1) 543 (21.6) –0.062
Disease-modifying antirheumatic drug 33 (1.2) 25 (1.0) 0.021
Anticoagulant 27 (1.0) 22 (0.9) 0.012
(continued)
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randomized to the CEA treatment compared with those ran-
domized to initial medical therapy (5.6% vs 7.8%; risk differ-
ence, −2.3% [95% CI, −4.0% to −0.3%]) (Figure 2, Table 2). A
5-year risk difference of 2.3% corresponded to an annualized
stroke risk difference of 0.46% and a number needed to treat
(NNT) of 43 over 5 years.
The 5-year cumulative incidence function, accounting
for competing risks for patients in the CEA cohort and those
in the initial medical therapy cohort in the pragmatic
sample, is seen in Figure 3. The stroke risk at 5 years of
follow-up was 5.4% (95% CI, 4.7%-6.2%) in the CEA cohort
and 6.2% (95% CI, 5.7%-9.5%) in the initial medical therapy
cohort (Table 2). The risk difference between the 2 cohorts
when the competing risk of death was taken into consider-
ation was smaller than previously observed and not statisti-
cally significant at the α = .05 level (risk difference, –0.8%;
95% CI, –2.1% to 0.5%). This finding suggests that little to no
difference existed between CEA and initial medical therapy
Table 1. Baseline Characteristics of Patients in Both Treatment Cohorts (continued)
Characteristic
No. (%)
Standardized
difference
CEA cohort
(n = 2712)
Initial medical
therapy cohort
(n = 2509)
Adherence
Adherence to antihypertension medication
Yes 1839 (67.8) 1725 (68.8) –0.020
No 561 (20.7) 499 (19.9) 0.020
Not hypertensive 312 (11.5) 285 (11.4) 0.005
Adherence to statin therapy
Yes 1255 (46.3) 1184 (47.2) –0.018
No 819 (30.2) 765 (30.5) –0.006
Not receiving statin therapy 638 (23.5) 560 (22.3) 0.029
Trial exclusion
Acute myocardial infarction in past 30 d 25 (0.9) 18 (0.7) 0.023
PCI or CABG in past 30 d 10 (0.4) 9 (0.4) 0.017
Troponin level elevation in past yeara 120 (4.4) 114 (4.5) –0.006
Unstable angina in past year 26 (1.0) 26 (1.0) –0.008
Severe CHF diagnosisa 75 (2.8) 69 (2.8) 0.001
Severe COPD diagnosisa 155 (5.7) 143 (5.7) 0.001
Dialysis 16 (0.6) 14 (0.6) 0.004
Poorly controlled diabetes (HbA1c >9) 137 (5.1) 110 (4.4) 0.032
Gastrointestinal bleed in past 3 mo 33 (1.2) 21 (0.8) 0.037
Cancer diagnosis or treatment in past year 221 (8.2) 181 (7.2) 0.035
Dementia 80 (3.0) 95 (3.8) –0.046
Coagulopathy 41 (1.5) 46 (1.8) –0.025
Platelet count <100 000/μL 26 (1.0) 14 (0.6) 0.046
Abbreviations: BP, blood pressure;
CABG, coronary artery bypass graft;
CEA, carotid endarterectomy; DVT,
deep vein thrombosis; EF, ejection
fraction; GFR, glomerular filtration
rate; HbA1c, hemoglobin A1c; HMO,
health maintenance organization;
PCI, percutaneous coronary
intervention; PE, pulmonary
embolism; TIA, transient ischemic
attack.
a Troponin level elevation was not a
formal trial exclusion criterion; we
used it to identify patients at higher
cardiovascular risk. Severe
congestive heart failure included
patients with EF less than 35%;
severe chronic obstructive
pulmonary disease included
patients with a forced expiratory
volume in the first second of
expiration less than 30% predicted.
Table 2. Five-Year Stroke Risks in the Pragmatic and Randomized Clinical Trial–like Samples
Sample
% (95% CI)
Perioperative
complications
(stroke or death risk
at 30 d)
CEA cohort 5-y
stroke risk
Initial medical therapy
cohort 5-y stroke risk
Risk
difference
Pragmatic sample
Actual treatment
receiveda
2.5 (2.0 to 3.1) 7.5 (6.5 to 8.7) 6.9 (5.8 to 8.1) NA
Emulation of ACST NA 5.6 (4.6 to 6.5) 7.8 (6.3 to 9.3) –2.3 (–4.0 to –0.3)
After accounting
for competing risks
NA 5.4 (4.7 to 6.2) 6.2 (5.7 to 9.5) –0.8 (–2.1 to 0.5)
RCT-like sample
Actual treatment
receiveda
2.4 (1.8 to 3.2) 6.7 (5.6 to 8.0) 6.2 (5.1 to 7.6) NA
Emulation of ACST NA 5.5 (4.5 to 6.5) 7.6 (5.7 to 9.5) –2.1 (–4.4 to –0.2)
After accounting for
competing risks
NA 5.3 (4.5 to 6.2) 6.2 (4.7 to 8.1) –0.9 (–2.9 to 0.7)
Abbreviations: ACST, Asymptomatic
Carotid Surgery Trial3; CEA, carotid
endarterectomy; NA, not applicable;
RCT, randomized clinical trial.
a Obtained from the unadjusted
Kaplan-Meier survivor function
estimates.
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when the competing risk of nonstroke death was incorpo-
rated into the analysis.
RCT-like Sample
Observed Risk of Stroke and Death per Actual Treatment Received
Among the 5221 total patients in the CEA and initial medical
therapycohorts in thepragmatic sample, 1319 (25.3%)wereex-
cludedbecauseofbaselinecomorbidities inconsistentwithRCT
inclusion criteria. Thus, the RCT-like sample comprised 3902
patients (1890 in the CEA cohort and 2012 in the initial medi-
cal therapy cohort).
The observed risk of stroke or death (perioperative com-
plications) within 30 days in the CEA cohort was 2.4% (95%
CI, 1.8%-3.2%) in theRCT-like sample (Table 2). The observed
5-year risk of fatal or nonfatal stroke among patients with ca-
rotid stenosis in theRCT-like samplewas 6.7% (95%CI, 5.6%-
8.0%) in the CEA cohort andwas 6.2% (95%CI, 5.1%-7.6%) in
the initialmedical therapy cohort. In theRCT-like sample, the
5-year survival was 77.3% (95% CI, 75.4%-79.1%) in the CEA
cohort and 71.9% (95% CI, 69.8%-73.9%) in the initial medi-
cal therapy cohort.
Target Trial Results
Thebaseline characteristics of thepropensity-matched sample
comparing the CEA cohort with the initial medical therapy co-
hort before and after randomization are provided in eTables 8
and9 in theSupplement.Afteradjusting forbaselinecharacter-
istics and incorporating the IPCWamongpatientswhomet trial
inclusion criteria in the RCT-like sample, the resultswere simi-
lar to those observed in the pragmatic sample (Table 2). The
5-year riskof fatal andnonfatal strokeswas5.5%(95%CI,4.5%-
6.5%) among patients randomized to early CEA treatment and
was 7.6% (95% CI, 5.7%-9.5%) for those who received initial
medical therapy,with a riskdifferenceof −2.1% (95%CI, −4.4%
to −0.2%) (Table 2 and eFigure 1 in the Supplement). A 5-year
risk difference of 2.1% corresponded to anNNT of 47.
The 5-year cumulative incidence function, accounting for
competing risks amongpatients randomized to theCEA treat-
ment or to the initial medical therapy in the RCT-like sample,
is provided in eFigure 2 in the Supplement. The stroke risk at
5 years of follow-upwas 5.3% (95%CI, 4.5%-6.2%) in theCEA
cohort and 6.2% (95% CI, 4.7%-8.1%) in the initial medical
therapy cohort. Similar to the pragmatic sample, the risk dif-
ference in theRCT-like samplebetween the2cohortswhen the
competing risk of nonstroke death was taken into consider-
ation was not statistically significant at the α = .05 level (risk
difference, −0.9%; 95% CI, −2.9% to 0.7%) (Table 2).
Sensitivity Analysis
We examined the implication for the estimated stroke risk dif-
ference of excludingpatientswith either of the 2 baseline char-
acteristicsthathadastandardizeddifferencegreaterthan0.1(en-
rollment in a health maintenance organization and history of
remote stroke) (eTable 10 in the Supplement). After excluding
these patients, the risk difference remained −2.2% (95% CI,
−4.4%to0.1%).Wealsoconductedasensitivityanalysis inwhich
we excluded anyone enrolled in a health maintenance organi-
zation at baseline andduring follow-up. Again,we foundmini-
mal association with the stroke risk when comparing the CEA
cohort with the initial medical therapy cohort (risk difference,
−2.1%; 95%CI, −4.2% to −0.1%) (eTable 10 in the Supplement).
Discussion
WeusednationalVAandMedicaredata tomimic a carotid trial
similar indesignandanalysis to theACST, themost recentpub-
lished trial that compared CEA with initial medical therapy
amongpatientswithasymptomatic carotidstenosis.3 Similar to
the ACST, the survival curves in the pragmatic sample crossed
within 2 years of follow-up, and, as in theACST, higher stroke-
freesurvivalwasfoundamongpatientswhoreceivedCEA.How-
ever, the fatal and nonfatal stroke risk difference at 5 years be-
tween patients who were randomized to early CEA and those
randomized to initial medical therapy was 2.3% and was less
than the stroke risk difference of 5.4% (any stroke and peri-
operativedeath) reported in theACST.3This riskdifferencecor-
responded to an annualized net benefit in stroke reduction of
only0.46%peryearandanNNTof43at5years. Inotherwords,
43 patients needed to be revascularized within 1 year to avoid
a single fatal or nonfatal stroke within 5 years. In contrast, in
theACST, theNNTwasapproximately 18.3Furthermore, to test
the robustnessof this result to the competing riskofnonstroke
Figure 2. Survival Probability for Fatal and Nonfatal Strokes
in the Pragmatic Sample
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Figure 3. Cumulative Incidence Function of Fatal and Nonfatal Stroke
in the Pragmatic Sample
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death, we estimated cumulative incidence functions for fatal
andnonfatal strokes in theCEAand initialmedical therapy co-
horts,accountingforthecompetingriskofdeathassociatedwith
other causes. This analysis suggested that little to no differ-
ence existed between the 2 treatment strategies after account-
ing for competingcausesofdeath.Theseanalyses,when taken
together,suggestthat inreal-worldpracticemedical therapymay
be an equally acceptable treatment strategy for patients with
asymptomatic carotid stenosis.
We repeated theanalysis in theRCT-like sampleand found
similar results, which was contrary to our initial expecta-
tions. We hypothesized that the benefit of CEA could be ob-
servedmore readily in patients whomet trial inclusion crite-
ria because thesepatientsmay live longer, accruemore stroke
reduction, and have fewer perioperative complications. The
analysis confirmed that patients whomet the inclusion crite-
riawerehealthier andweremore likely tosurvive5years.How-
ever, the perioperative complication (stroke or death) risk ob-
served in the CEA cohort of the RCT-like sample was not
statistically significantly lower than the perioperative com-
plication rate in the pragmatic sample and was only some-
what lower than that observed in the ACST.3 The decreased
stroke risk in patientswith carotid artery stenosis, the persis-
tent up-front perioperative risks, and the small difference in
stroke risk between the2 treatment strategies suggest that pa-
tients treatedwithCEAwouldnowrequire a longer time to ac-
crue enough stroke reduction benefit to justify the up-front
risks of the surgical procedure.
This study confirmed the observation that the stroke risk
among patients with carotid stenosis has decreased.15 In the
pastdecade, strokehasdroppedfromthe third to the fifth lead-
ing cause of death in theUS.44 This improvement has been at-
tributed to several factors, including more aggressive diabe-
tes andhypertension control andadvances inmedical therapy
(eg, statins). The decrease in stroke risk in the initial medical
therapy cohort in thepresent studywas likely associatedwith
more effective control of atherosclerotic risk factors in theVA.
However,medical therapy couldbe improved inboth theCEA
and initial medical therapy cohorts. Over the past 2 decades,
the VA has been tracking blood pressure, glycemic, and lipid
targets andhas achieved substantial improvements in cardio-
vascular risk factor control.45 In addition, the stroke risk esti-
mated in the2 cohorts preceded thepublicationof theSAMM-
PRIS (Stenting and Aggressive Medical Management for
Preventing Recurrent Stroke in Intracranial Stenosis) trial,
which likely focusedevenmoreattentionon improving thede-
livery ofmedical care. It is possible that, with the use of high-
potency statins, the stroke risk has decreased even further.46
The analytic method used and the 2 alternative ap-
proaches considered in this comparative effectiveness study
deserve some discussion.39,40 The intervention (CEA) can be
applied at any time after carotid imaging, and thus a success-
ful analytical strategy accounts for and avoids immortal time
bias. First,we considered the landmark analysis, inwhichpa-
tients would be followed up from 1 year after the first carotid
image (the landmark date equals the image date plus 365
days).47,48 Patients for whom an event occurred between the
imagingdateand the landmarkdatewouldbeexcluded.Treat-
ment status would have been based on what occurred be-
tween the imaging date and the landmark date. Although the
landmark analysis approach would avoid immortal time bias
and allow for a clearly defined exposure, it would exclude all
of the early events. Consequently, the landmark analysis ap-
proachwould artificiallymake theCEA look safer because the
early perioperative stroke eventswouldbe removed. Further-
more, this approachwould provide limited information to in-
formclinicaldecision-makingbecauseall informationonearly
complications would be excluded.
Second,weconsideredtheCoxproportionalhazardsregres-
sionmodel inthefull sample, treatingthe interventionasatime-
varyingcovariateandreportingtheassociationbetweenCEAand
theoutcomeusingahazardratio.Patientswouldhavebeenclas-
sified in the initial medical therapy cohort until they under-
wentCEA, atwhich time theywouldhavebeenclassifiedasbe-
longing in the CEA cohort. Although the Cox approach would
avoidimmortaltimebiasandwouldbeanalyticallysimpletocon-
duct, it has a primary limitation. This approachwould result in
anestimationof a relativehazard ratio andwouldnot allow the
estimation of absolute treatment outcomes.
Using the target trialmethod,wewere able to estimate the
absolute reduction in the risk of the outcome and hence the
NNTsornumbersneeded toharm,which are important quan-
tities for medical decision-making. In contrast, the Cox pro-
portional hazards regression model would only allow for the
estimation of relative changes in the hazard of the outcome.
We have reported only absolute risks, risk differences, and
NNTs, none of which can be derived from the Cox approach
with time-varying covariates. Therefore, we chose the target
trial method to enable the analysis to both mimic an RCT, al-
lowing for comparisons with previously published trial re-
sults, and to account for immortal time bias and time-varying
confounding between the index imaging date and the treat-
ment randomization date.
Strengths and Limitations
This study has several strengths. First, the study used com-
prehensivedata forUSveterans.TheVAprovidesaccess to lon-
gitudinal data, Medicare data, the Corporate Data Ware-
house, and the SuicideData Repository; few comparable data
sources are available to researchers. Second, the sample size
was larger than theACST, allowingus to detect smaller differ-
ences in stroke risk. Third, even though the goal of the ongo-
ing CREST-2 (Carotid Revascularization EndarterectomyVer-
sus Stenting 2) trial34 is to examine the efficacy of CEA
compared with initial medical therapy in the era of modern
medical therapy, the results of the present study are informa-
tive and provide insights into the risks and benefits of carotid
revascularization in real-world settings inwhichpatientsmay
have greater perioperative complications and/or poor risk fac-
tor control compared with patients enrolled in RCTs. In com-
munity settings in which the competing risk of death is not
trivial, it appears that CEAmay offer no benefit.
This study has several limitations. First, although peri-
operative strokes were accounted for in the outcome of fatal
and nonfatal strokes across 5 years of follow-up, wewere un-
able to incorporate into the analysis the perioperative com-
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plication of death associatedwith CEA. Second,we used data
from the Suicide Data Repository to assess fatal stroke out-
comes. It is possible that, despite using standard, established
methods forassessingstroke intheadministrativedata,wemay
havemissed strokedeaths thatwerenot coded.29,38Third, this
study involved predominantly older male veterans. As such,
the findings may not be generalizable to the entire popula-
tion of patients who receive carotid intervention for asymp-
tomatic carotid stenosis. However, the results should be rel-
evant to older men in the Medicare population, which is the
cohort receiving most of the revascularizations in the US.49
Fourth, the implementation of the analytical strategy re-
quired censoring patients when their actual treatment be-
came discordant with the treatment to which they were ran-
domized per the target trial methods. This informative
censoring was accounted for usingmodel-based IPCWs, and,
aswithmostmethods used for analyzing observational stud-
ies, its success depended in part on the assumption that we
havemeasured an adequate set of variables to account for the
censoring. Although we had access to detailed clinical notes
and records, it is possible that patients’ actual treatment be-
came discordant with their randomized treatment for rea-
sons that we were unable to capture.
Conclusions
The absolute reduction in the risk of fatal and nonfatal strokes
associatedwith early CEA intervention found in this study ap-
peared to be less thanhalf the risk difference observed in trials
initiatedmore than 2 decades ago. This reduction was no lon-
ger statistically significant when the competing risk of non-
strokedeathswere accounted for in theanalysis.Given theup-
front perioperative risks associated with CEA, initial medical
therapymaybeanequallyacceptable treatmentstrategy for the
management of patients with asymptomatic carotid stenosis.
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